APA (7th ed.) Citation

Leiter, L. A., Bain, S. C., Hramiak, I., Jódar, E., Madsbad, S., Gondolf, T., . . . Lingvay, I. (2019). Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: A post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovascular diabetology, 18(1), 73-12. https://doi.org/10.1186/s12933-019-0871-8

Chicago Style (17th ed.) Citation

Leiter, Lawrence A., Stephen C. Bain, Irene Hramiak, Esteban Jódar, Sten Madsbad, Theis Gondolf, Thomas Hansen, Ingrid Holst, and Ildiko Lingvay. "Cardiovascular Risk Reduction with Once-weekly Semaglutide in Subjects with Type 2 Diabetes: A Post Hoc Analysis of Gender, Age, and Baseline CV Risk Profile in the SUSTAIN 6 Trial." Cardiovascular Diabetology 18, no. 1 (2019): 73-12. https://doi.org/10.1186/s12933-019-0871-8.

MLA (9th ed.) Citation

Leiter, Lawrence A., et al. "Cardiovascular Risk Reduction with Once-weekly Semaglutide in Subjects with Type 2 Diabetes: A Post Hoc Analysis of Gender, Age, and Baseline CV Risk Profile in the SUSTAIN 6 Trial." Cardiovascular Diabetology, vol. 18, no. 1, 2019, pp. 73-12, https://doi.org/10.1186/s12933-019-0871-8.